Background. The efficacy of tenofovir disoproxil fumarate (TDF) as part of combination antiretroviral treatment (ART) has been demonstrated in several randomized, controlled trials. However, an increasing number of case reports suggest that TDF use may be associated with significant nephrotoxicity. Our objective was to determine the renal safety of TDF-containing ART regimens for HIV-infected individuals.
nephrotoxicity significant enough to limit its use or to necessitate close clinical monitoring [4] [5] [6] .
Concerns regarding nephrotoxicity were initially raised by the structural similarity between TDF and the acyclic nucleotide analogues adefovir and cidofovir, both established causes of clinically important renal dysfunction and hypophosphatemia [7] . Preclinical studies suggested a weakly cytotoxic effect of TDF on renal tubular cells in vitro [8, 9] , and animal studies revealed renal tubular toxicity when very high doses of TDF were used [10] . Supporting these theoretical concerns, multiple case reports have linked TDF use with proximal tubulopathy, diabetes insipidus, decreased bone density, and impaired glomerular filtration [4, [11] [12] [13] . Additionally, several observational cohort studies have associated modest rates of renal dysfunction with TDF use [14] [15] [16] [17] [18] [19] [20] with one study finding a 1% yearly incidence of nephrotoxicity severe enough to warrant discontinuation of TDF therapy [16] .
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of potent ART has led to increased emphasis on monitoring for potential cumulative, long-term toxicities of ART. Acknowledging the potential for nephrotoxicity, recent guidelines recommend biannual monitoring of renal function in HIV patients receiving TDF [1, 6] . However, frequent laboratory monitoring for very rare toxicity may unnecessarily limit the use of TDF in resource-limited settings [21] . Therefore, a more precise estimate of the risk of nephrotoxicity would be useful for clinicians and policy makers. We performed a systematic review and meta-analysis of comparative studies to determine the renal safety of TDF-containing ART regimens in HIV-infected individuals.
METHODS
This study was conducted and reported in accordance with available guidelines as described below [22, 23] .
Search strategy. We conducted a comprehensive search strategy designed by a Master of Library and Information Science program-trained librarian to identify all relevant comparative studies of tenofovir use in HIV-infected patients. Inclusion was restricted to studies published in English as full manuscripts. MEDLINE Table A1 in the Appendix, which appears only in the electronic version of the journal.
Selection criteria. Two reviewers independently assessed each potentially relevant study for eligibility. Disagreements were resolved by consultation with a third party. Inclusion was limited to studies of prospective, comparative design (randomized, controlled trials; secondary analyses of cohort-nested randomized, controlled trials; and prospective and registry cohort data) that systematically reported renal outcomes (including renal failure, serum creatinine levels, estimated creatinine clearance using Cockcroft-Gault calculation [CG-GFR], estimated glomerular filtration rate using the modification of diet in renal disease calculation [MDRD-GFR], proteinuria, or albuminuria) and that were conducted involving HIV-infected patients. Treatment groups had to have a minimum of 10 participants in each group, and groups had to be followed for a minimum of 2 weeks.
Data extraction. A standardized data-extraction method was used to record relevant properties of each trial into a da- tabase: study characteristics (country, design, sample size, and duration of therapy), characteristics of participants (age, sex, baseline renal function, viral load, and CD4 cell count), therapeutic interventions, and control regimen. Outcomes assessed included renal failure, serum creatinine level, CG-GFR, MDRD-GFR, bone mineral density, fractures, hypophosphatemia, proteinuria, and albuminuria. We intended to collect data on albumin level, blood pressure, hematuria, hemoglobin level, incident hypertension, and hypercalcemia but did not find data on these characteristics in eligible studies. A second reviewer checked the extracted data for accuracy. Quality assessment. The study quality was assessed using a condensed version of the Downs and Black checklist [24] , and assessment included other items also known to be associated with study quality [25, 26] . Source of funding was also extracted, given its potential to introduce bias [27] .
Data analysis. Data were analyzed using Stata, version 10.1 (Stata Corp). Missing standard deviations were imputed in accordance with Wiebe et al [28] . Because of the differences expected between studies, we combined results using a random effects model [29] . Statistical heterogeneity was quantified using the statistic [30, 31] . A priori we planned to examine the 2 I association between certain variables (study design, prior use of ART, duration of follow-up, ARTs used in combination with tenofovir, and quality criteria) and the effect of tenofovir on the outcomes. We performed univariable, weighted, leastsquares meta-regressions to identify trial-level characteristics associated with the risk of the clinical outcomes [32] . Publication bias was assessed using Egger's method [33] .
RESULTS
Quantity of research available. The literature searches revealed a total of 1253 citations. From these, 95 articles were retrieved for further scrutiny. A total of 79 articles were excluded for reasons detailed in Figure 1 , resulting in 17 primary articles [16] [17] [18] [19] [20] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] that met the selection criteria. Disagreements occurred for 6 (8%) of the 79 excluded articles (k p ) and concerned type of control (3 studies), outcome (2 0.77 studies), and study design (1 study). Of the 6 articles on which there was initial disagreement, 3 were ultimately included.
Study characteristics. Of the 17 studies included in the present analysis, 9 [34, 35, 37, 38, [41] [42] [43] [44] [45] were randomized, controlled trials, of which 5 were double blinded. Seven studies used prospective observational cohort designs [16-20, 39, 40] . One study used prospectively collected data from an adverse events registry [36] .
The median study duration was 48 weeks (range, 24-144 weeks) and, for this analysis, was considered equivalent to time receiving treatment. Sample size ranged from 49 to 3439 participants (median, 517 participants).
The studies varied greatly with respect to the specific anti- Description of losses to follow-up (% of patients)
Yes (6) Yes (4) Yes (15) Yes (11) Yes (4) Yes (15) Yes (3) Yes (17) Yes ( retroviral agent used as comparator and with respect to allowed antiretroviral cointerventions (Tables 1 and 2 ). In several of the studies reviewed, TDF was not the only antiretroviral agent that differed between the treatment and control groups. However, despite the variations in ART combinations, each study allowed for comparison of an ART regimen containing TDF with a regimen not containing TDF. Eleven studies recruited only participants who were ART experienced, 3 studies [34, 38, 44] recruited only participants who were ART naive, and 3 studies [16, 17, 36] included both ART-naive and ART-experienced participants. Quality assessment is reported in Tables 3 and 4 . Treatment assignment was concealed in 5 of 9 trials. Reporting of losses to follow-up and adverse events was adequate in all trials.
The mean age of participants across the included studies ranged from 34 to 45 years, and the proportion of participants who were male ranged from 59% to 100% (median, 82%). The proportion of African American participants ranged from 0% to 74% (median, 25%). Of the 17 studies, 10 reported mean baseline CG-GFR (range, 100-135 mL/min). Mean baseline viral load ranged from 2.4 to 5.2 log 10 copies/mL (median, 4.1 log 10 copies/mL), and mean baseline CD4 cell count ranged from 197 to 561 cells/mL (median, 356 cells/mL). The majority of studies (67%) were funded, at least in part, by pharmaceutical industry-related sources.
Publication bias. To investigate the potential for publication bias, results from analyses comparing renal function loss (as estimated by CG-GFR) between groups receiving TDF and groups not receiving TDF were assessed using a funnel plot. Our funnel plot appeared asymmetrical ( Figure A1 in the Appendix), suggesting either evidence of missing small studies with either no change or increases in kidney function or statistical heterogeneity of another kind. The weighted regression test detected statistical evidence of bias (bias, Ϫ1.9;
). P p .005 Renal outcomes. Eleven studies [16-20, 34, 37, 38, 40, 41, 44] (total of 5767 participants) reported change in renal function as estimated by CG-GFR. There was a significantly greater loss of kidney function over the course of treatment among those receiving TDF-containing ART, compared with control subjects (mean difference [MD] in CG-GFR, 3.92 mL/min; 95% confidence interval [CI], 2.13-5.70 mL/min) (Figure 2 ). The statistical heterogeneity for this outcome was large ( 2 I p ). Six studies [20, 34, 37, 39, 40, 44] (total of 2334 par-66% ticipants) reported the change in MDRD-GFR. The difference in change of kidney function was not significantly different between groups (MD, 2.56 mL/min; 95% CI, Ϫ0.57 to 5.69 mL/min), and statistical heterogeneity was large ( ).
2
I p 78% We performed univariable meta-regression to further explore factors that might account for the observed between-study heterogeneity of the effect of TDF on renal function. Potential explanatory variables considered were study design, prior ART treatment, duration of follow-up, use of protease inhibitors, intention-to-treat design, and description of adverse events (Table 5). We found that the degree of TDF-associated renal func- tion loss was significantly smaller in experimental trials than in studies of observational design (mean decrease in CG-GFR, Ϫ1.50 vs Ϫ5.45 mL/min; difference in TDF-associated renal function loss, 4.32 mL/min; 95% CI, 2.15-6.49 mL/min). We also found a trend toward greater degree of TDF-associated renal function loss in studies involving ART-experienced participants, compared with studies involving ART-naive participants, but this was of borderline statistical significance (mean decrease in CG-GFR, Ϫ2.50 vs Ϫ5.15 mL/min; difference in TDF-associated renal function loss, 2.92 mL/min; 95% CI, 6.02 to Ϫ0.18 mL/min). Finally, we observed a trend in univariate analysis whereby TDF-associated renal function loss was smaller in industry-sponsored studies than in non-industry-sponsored studies (TDF-associated renal function loss in studies with industry funding was 3.57 mL/min less than that in studies without industry funding (95% CI, Ϫ0.62 to 7.77). Extensive colinearity between many of the variables precluded multivariable analysis. Eight studies [19, 20, 36-38, 40, 41, 44] (total of 7496 participants) reported the incidence of acute renal injury (variably defined in each study). We found a small but significantly increased risk of acute renal injury associated with TDF-containing regimens (risk difference, 0.7%; 95% CI, 0.2-1.2; statistical heterogeneity absent:
). However, no significant 2 I p 0% risk differences were found for chronic kidney failure (0.2%; 95% CI, Ϫ1.5 to 0.2) or end-stage kidney failure requiring long-term dialysis (0.2%; 95% CI, Ϫ0.3 to 0.7).
Six studies [19, 34, 35, 38, 40, 43] (total of 2320 participants) reported the incidence of grade 3/4 proteinuria (defined as "4+ protein" on semiquantitative urine dipstick assay or 12 g/day of urine protein excretion). We detected no difference in rates of significant proteinuria between those receiving TDF-containing ART and control subjects (risk difference, 0.0% ; 95% CI, Ϫ0.4 to 0.4; statistical heterogeneity absent:
).
I p 0% There was also no detectable difference between groups in risk of lesser degrees of proteinuria, although statistical heterogeneity for these estimates was large (data not shown).
Bone outcomes. Only 2 of the included studies [34, 38] (total of 1111 participants) reported incidence of bone fracture. The risk ratio for participants receiving TDF-containing ART, compared with control subjects, was not significant (0.58; 95% CI, 0.28-1.22;
I p 0% Four studies reported bone mineral density outcomes [38, [41] [42] [43] (total of 1224 participants). There was no difference in the degree of bone density loss between those receiving TDFcontaining ART and control subjects (standardized mean difference, 0 standard deviations; 95% CI, Ϫ0.16 to 0.16; modest statistical heterogeneity:
I p 26% Three studies [20, 38, 45] (total of 1402 participants) reported incidence of serum hypophosphatemia, but none found a significantly increased risk among TDF recipients. The relative risk for grades 3/4 serum hypophosphatemia, defined as !1.5 mg/dL, was 0.34 (95% CI, 0.05-2.31); the relative risk for grades 2 or 3 hypophosphatemia, defined as 1-1.9 mg/dL, was 1.44 (95% CI, 0.60-3.44), and the relative risk for grade 1 hypophosphatemia, defined as 2-2.2 or 2.4 mg/dL was 1.42 (95% CI, 0.79-2.57). There was no statistical heterogeneity for these outcomes ( ). [20] . The other studies are indicated by first author and date of publication [16-19, 34, 37, 38, 40] . ART, antiretroviral treatment; CI, confidence interval; MD, mean difference; NNRTI, nonnucleoside reverse-transcriptase inhibitor; RCT, randomized controlled trial; RPI, ritonavir-boosted protease inhibitor.
DISCUSSION
We identified 17 eligible studies, including 10,889 participants, and found that TDF-containing ART regimens were associated with a significantly greater loss of kidney function than were ART regimens not containing TDF. We also found a significantly higher risk of acute renal injury associated with TDF use. Although the observed differences were statistically significant, their magnitude was modest in clinical terms. We did not find an increased risk of proteinuria, hypophosphatemia, decreased bone mineral density, or bone fractures in patients taking TDF-containing ART; however, few studies systematically measured these specific outcomes.
Our findings are consistent with the results of industry-sponsored, postmarketing adverse events surveillance [46] . Across an estimated 400,000 person-years of TDF exposure, !0.2% of patients were judged to have experienced severe renal failure. Similarly, in a retrospective, noncomparative cohort study of 11000 HIV-infected individuals receiving TDF-containing ART, !1% experienced moderately severe renal toxicity (defined as serum creatinine level 1120 mmol/L) considered to be due to TDF [47] . Taken together with the findings of these observational studies, our systematic review suggests that the risk of clinically relevant renal toxicity due to TDF is relatively low, at least during short-term follow-up.
Discrepancy between our results and multiple published case reports. Notwithstanding the findings of our review, dozens of sporadic cases of TDF-associated renal dysfunction have been reported [48] . How can findings of the current review be reconciled with the increasing number of such case reports [11-13, 46, 48-58] ?
Several clinical features of TDF-associated nephrotoxicity have been consistently observed in available case series [48, 51, 54, 57, 58] . First, most reported cases of TDF-associated nephrotoxicity involved a specific pattern of renal injury: proximal renal tubulopathy, sometimes with frank Fanconi syndrome, occurring together with reduced GFR. It is possible that detection of early or mild cases of TDF-associated nephrotoxicity would require specific testing for proximal tubule injury (eg, urinanalysis, measurement of bone density, serum phosphate level, or bone fracture rate). Such specific testing was not generally performed in the studies included in our meta-analysis.
Second, most reported cases involved the concomitant use of didanosine and/or a ritonavir-boosted protease inhibitor [59] . Furthermore, several observational studies have suggested that interactions between TDF and other antiretroviral agents may contribute to the development of TDF-associated nephrotoxicity [13, 15, [60] [61] [62] . It is worth noting then that many of the studies included in the present review typically combined TDF with nonnucleoside reverse-transcriptase inhibitor-based ART (rather than a ritonavir-boosted regimen), and didanosine use was specifically avoided.
Third, many case reports of TDF-associated nephrotoxicity occurred in older patients, those with advanced HIV disease, or those with mild baseline renal dysfunction [59] -such patients were often excluded from the trials included in our metaanalysis. Other inclusion and exclusion criteria for these trials may have led to the selection of a relatively healthier group of patients who were at lower-than-average risk of TDF-induced renal dysfunction.
As an illustration of the potential for selection bias to hide potentially relevant TDF-associated nephrotoxicity, we performed exploratory post hoc analysis using meta-regression techniques. We found that subjects included in clinical trials appeared to have slower rates of TDF-associated kidney function loss than did patients treated in observational clinical cohort studies. While experimental trials often study highly select patient groups, observational studies often include a broad range of relatively unselected patients, many of whom may have clinical factors predisposing them to TDF-associated nephrotoxicity. Precisely which clinical features predispose to TDFassociated nephrotoxicity, however, are largely unknown and could not be ascertained in our current review. Nonetheless, our findings together with recently reported observational data from the Development of Antiretroviral Therapy in Africa (DART) trial team in East Africa provide some reassurance that TDF-based ART can be provided safely without close monitoring of renal function [63] .
Limitations of the current study. Like all systematic reviews, the strength of our conclusions is limited by the available evidence. First, the large statistical heterogeneity observed in our study (perhaps reflecting differences in study populations) highlights the potential importance of patient selection for our findings. Second, most of the studies we identified were conducted in high-income countries; future trials should focus on patients treated in resource-limited settings [62] . Third, we identified too few studies that included patient-level information on concomitant use of regimens containing ritonavirboosted protease inhibitors and thus could not perform metaregression or post hoc subgroup analysis to explore this as a possible effect-modifier of TDF-associated nephrotoxicity. Fourth, many studies did not report markers of proximal tubulopathy or bone health; thus, it is possible that our analysis was underpowered for these outcomes. Future studies should assess the impact of TDF on consequences of proximal tubulopathy (such as proteinuria, bone mineral density, and bone fractures) to ensure that clinically important cumulative toxicity is not missed. Finally, most trials were short-term in duration; therefore, our findings may not apply to patients exposed to TDF for prolonged periods. However, experience from published case series and from available cohort studies suggests that TDF-associated nephrotoxicity may occur more typically within the first few months of exposure [4, 17, 61] . Whether the risk for TDF-associated nephrotoxicity increases with prolonged use or is cumulative is of critical importance and would be an important area of future study; especially given recent clinical practice recommendations to start ART earlier in the course of HIV infection [63] . Summary and implications. Although our review identified a statistically significant loss of renal function associated with TDF use, the clinical magnitude of this effect was modest. Further research is needed, especially long-term studies that monitor clinically relevant markers of proximal tubulopathy. Nonetheless, our findings do not support the need to restrict TDF use in jurisdictions where regular monitoring of renal function and serum phosphate levels is difficult or impractical.
